Boster Immunoleader

antibody

Anti-Dopamine Receptor D5 Antibody

PA2204

100 ug/vial

200 USD

polyclonal

rabbit

human, mouse, rat

Anti-Dopamine Receptor D5 Antibody

PA2204

Polyclonal

Rabbit IgG polyclonal antibody for D(1B) dopamine receptor(DRD5) detection. Tested with WB in Human;Mouse;Rat.

200 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human, mouse, rat

WB

Concentration: 0.1-0.5μg/ml; Tested Species: Human, Mouse, Rat

Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. Other applications have not been tested. Optimal dilutions should be determined by end users.

A synthetic peptide corresponding to a sequence at the C-terminus of mouse Dopamine Receptor D5(388-407aa LISYNQDTVFHREIAAAYVH), different from the related rat sequence by two amino acids, and from the related human sequence by three amino acids.

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB.

D(1B) dopamine receptor(DRD5), also called DRD1B or DRD1L2 is a protein that in humans is encoded by the DRD5 gene. This gene is mapped to 4p16.1. This gene encodes the D5 subtype of the dopamine receptor. The D5 subtype is a G-protein coupled receptor which stimulates adenylyl cyclase. This receptor is expressed in neurons in the limbic regions of the brain. It has a 10-fold higher affinity for dopamine than the D1 subtype. Pseudogenes related to this gene reside on chromosomes 1 and 2. Compared with DRD1, DRD5 displayed a higher affinity for dopamine and was able to stimulate a biphasic rather than a monophasic intracellular accumulation of cAMP.

1. Li, H., Armando, I., Yu, P., Escano, C., Mueller, S. C., Asico, L., Pascua, A., Lu, Q., Wang, X., Villar, V. A. M., Jones, J. E., Wang, Z., and 9 others. Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. J. Clin. Invest. 118: 2180-2189, 2008. Note: Erratum: J. Clin. Invest. 118: 2986 only, 2008. 2. Lowe, N., Kirley, A., Hawi, Z., Sham, P., Wickham, H., Kratochvil, C. J., Smith, S. D., Lee, S. Y., Levy, F., Kent, L., Middle, F., Rohde, L. A., and 20 others. Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes. Am. J. Hum. Genet. 74: 348-356, 2004. 3. Misbahuddin, A., Placzek, M. R., Chaudhuri, K. R., Wood, N. W., Bhatia, K. P., Warner, T. T. A polymorphism in the dopamine receptor DRD5 is associated with blepharospasm. Neurology 58: 124-126, 2002.

DRD5

D(1B) dopamine receptor

dopamine receptor D5

D(1B) dopamine receptor antibody D(5) dopamine receptor antibody D1 beta dopamine receptor antibody D1B dopamine receptor antibody D1beta dopamine receptor antibody D5 dopamine receptor antibody DBDR antibody Dopamine D5 receptor antibody Dopamine receptor D1B antibody DRD 1B antibody DRD 5 antibody DRD1B antibody DRD1L2 antibody DRD5 antibody DRD5_HUMAN antibody MGC10601 antibody

Q8BLD9